Document Detail


The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease.
MedLine Citation:
PMID:  12202858     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Postoperative pulmonary hypertension in children after surgical intervention for congenital heart disease has been attributed to failure of the pulmonary endothelium to provide adequate vasodilation. Although we have shown that the impaired vasodilatory component attributable to the l-arginine-nitric oxide pathway is almost completely reversible, a nonrestorable component persists, implying an additional vasoconstrictive mechanism in postoperative pulmonary endothelial dysfunction. In this study of children after surgical intervention for congenital heart disease, we measured endothelin-1 levels and used BQ123, a selective endothelin-A receptor antagonist, together with inhaled nitric oxide to discriminate dysfunctional pulmonary endothelial vasodilation from endothelin-mediated pulmonary vasoconstriction. METHODS: All children were examined early after surgical intervention in the intensive care unit. Pulmonary vascular resistance (with respiratory mass spectrometry), as well as arterial and venous endothelin-1 levels (measured by means of a quantitative enzyme-linked immunosorbent assay), were determined in 7 children (age range, 3.3-13.7 months; median age, 6.3 months) with intracardiac shunting defects at baseline and during ventilation with a fraction of inspired oxygen of 0.65, with additional BQ123 (0.1 mg/kg infused over 20 minutes), and with inhaled nitric oxide (20 ppm). RESULTS: Pulmonary vascular resistance decreased from 7.7 +/- 3.4 at baseline to 6.1 +/- 2.8 Woods units. m(-2) (P =.022) at a fraction of inspired oxygen of 0.65 and to 4.7 +/- 2.7 Woods units. m(-2) (P =.013) during BQ123 infusion. Inhaled nitric oxide had no further effect on pulmonary vascular resistance. Left atrial endothelin-1 levels (1.35-5.12 pg/mL; mean, 2.4 pg/mL) correlated significantly with the decrease in pulmonary vascular resistance in response to BQ123 infusion (r(2) = 0.89, P =.003). CONCLUSION: Postoperative elevation of pulmonary vascular resistance in children after surgical intervention for congenital heart disease is responsive to endothelin-A blockade with BQ123. Increased levels of endothelin-1 predict the response to this therapy, which might become an important addition to the clinical armamentarium in postoperative pulmonary hypertensive disease.
Authors:
Ingram Schulze-Neick; Jia Li; Jayne A Reader; Lara Shekerdemian; Andrew N Redington; Daniel J Penny
Related Documents :
12684298 - Spirometric variability in a longitudinal study of school-age children.
7212308 - Connective tissue arrangement in respiratory airways.
12611668 - Association of lung function with declining ambient air pollution.
16951798 - Evaluation of the dead space to tidal volume ratio as a predictor of extubation failure.
21819758 - The effect of passive smoking on the levels of matrix metalloproteinase 9 in nasal secr...
9505288 - Evaluation of a swedish version of the hearing disabilities and handicaps scale, based ...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  124     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-30     Completed Date:  2002-10-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  435-41     Citation Subset:  AIM; IM    
Affiliation:
Cardiac Intensive Care Unit, Department of Vascular Biology and Pharmacology, and Cardiothoracic Unit, Great Ormond Street Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antihypertensive Agents / therapeutic use*
Cardiopulmonary Bypass*
Child
Child Welfare
Child, Preschool
Endothelin-1 / blood,  drug effects
Heart Defects, Congenital / surgery*
Hemodynamics / drug effects
Humans
Infant
Infant Welfare
Infusions, Intravenous
London
Lung / blood supply*
Nitric Oxide / administration & dosage
Oxygen / administration & dosage
Peptides, Cyclic / therapeutic use*
Predictive Value of Tests
Pulmonary Veins / drug effects,  physiology
Pulmonary Wedge Pressure / drug effects,  physiology
Receptor, Endothelin A
Receptors, Endothelin / antagonists & inhibitors*,  therapeutic use*
Treatment Outcome
Vascular Resistance / drug effects*
Vasodilation / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Peptides, Cyclic; 0/Receptor, Endothelin A; 0/Receptors, Endothelin; 10102-43-9/Nitric Oxide; 136553-81-6/cyclo(Trp-Asp-Pro-Val-Leu); 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Criterion validity of the Duke Activity Status Index for assessing functional capacity in patients w...
Next Document:  Septation of the single ventricle: revisited.